title: [Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia].
abstract: The study aimed to assess the influence of long-term rhuEPO treatment on secretion of pancreatic hormones (insulin, glucagon). A total of 27 haemodialyzed and 9 healthy subjects were examined. Nine patients with uraemic anaemia were treated with rhuEPO for 12 months (EPO group) while another nine patients did not receive rhu-EPO (non-EPO group), but were monitored biochemically and clinically as patients of the EPO group. The third group (HD) comprised nine haemodialyzed patients with a haematocrit value of > 30%, without rhu-EPO therapy. In all subjects plasma levels of glucose, insulin (IRI) and glucagon (Glu) were estimated before and after administration of the test meal. Patients of the EPO and non-EPO group were examined before and after 6 and 12 months of rhu-EPO treatment (EPO group) or clinical monitoring (non-EPO group) respectively, while only one test was performed in patients of the HD group and healthy subjects. During the observation period fasting glicaemia did not change. Six months of rhu-EPO therapy was followed by an increase of fasting insulinaemia and decrease of basal plasma level of glucagon. At that time point rhu-EPO therapy also increased the response of IRI and Glu to the test meal and the insulin/glucose index. After 12 months of rhu-EPO therapy basal insulinaemia and insulin/glucose index returned to the pretreatment value while plasma level of glucagon and the response to the test meal were lower than pretreatment one. Our results suggest that rhu-EPO treatment exerts a profound effect on carbohydrate metabolism and secretion of IRI. Glu, which seems to be dependent upon duration of rhu-EPO therapy and not only, or exclusively to improvement of the haematological status.
authors.affiliation: Katedra i Klinika Nefrologii Sl.AM. w Katowicach.
authors.forename: T
authors.initials: T
authors.lastname: Nieszporek
authors.forename: F
authors.initials: F
authors.lastname: Kokot
authors.forename: A
authors.initials: A
authors.lastname: Wiecek
authors.forename: W
authors.initials: W
authors.lastname: Marcinkowski
authors.forename: R
authors.initials: R
authors.lastname: Rudka
authors.forename: J
authors.initials: J
authors.lastname: Trembecki
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D050260:Carbohydrate Metabolism; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D007328:Insulin / Q000097:blood; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008875:Middle Aged; D010187:Pancreatic Hormones / Q000378:metabolism*; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014511:Uremia / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D007328:Insulin; D010187:Pancreatic Hormones; D011994:Recombinant Proteins; D004921:Erythropoietin